Literature DB >> 26932931

Inhibitors of pendrin anion exchange identified in a small molecule screen increase airway surface liquid volume in cystic fibrosis.

Peter M Haggie1, Puay-Wah Phuan1, Joseph-Anthony Tan1, Lorna Zlock2, Walter E Finkbeiner2, A S Verkman3.   

Abstract

Pendrin (SLC26A4) is a Cl(-)/anion exchanger expressed in the epithelium of inflamed airways where it is thought to facilitate Cl(-) absorption and HCO3 (-) secretion. Studies using pendrin knockout mice and airway epithelial cells from hearing-impaired subjects with pendrin loss of function suggest involvement of pendrin in inflammatory lung diseases, including cystic fibrosis (CF), perhaps by regulation of airway surface liquid (ASL) volume. Here we identified small-molecule pendrin inhibitors and demonstrated their efficacy in increasing ASL volume. A cell-based, functional high-throughput screen of ∼36,000 synthetic small molecules produced 3 chemical classes of inhibitors of human pendrin. After structure-activity studies, tetrahydropyrazolopyridine and pyrazolothiophenesulfonamide compounds reversibly inhibited pendrin-facilitated Cl(-) exchange with SCN(-), I(-), NO3 (-), and HCO3 (-) with drug concentration causing 50% inhibition down to ∼2.5 μM. In well-differentiated primary cultures of human airway epithelial cells from non-CF and CF subjects, treatment with IL-13, which causes inflammation with strong pendrin up-regulation, strongly increased Cl(-)/HCO3 (-) exchange and the increase was blocked by pendrin inhibition. Pendrin inhibition significantly increased ASL depth (by ∼8 μm) in IL-13-treated non-CF and CF cells but not in untreated cells. These studies implicate the involvement of pendrin-facilitated Cl(-)/HCO3 (-) in the regulation of ASL volume and suggest the utility of pendrin inhibitors in inflammatory lung diseases, including CF.-Haggie, P. M., Phuan, P.-W., Tan, J.-A., Zlock, L., Finkbeiner, W. E., Verkman, A. S. Inhibitors of pendrin anion exchange identified in a small molecule screen increase airway surface liquid volume in cystic fibrosis. © FASEB.

Entities:  

Keywords:  ASL; drug discovery; high-throughput screening; inflammatory airway disease

Mesh:

Substances:

Year:  2016        PMID: 26932931      PMCID: PMC4871793          DOI: 10.1096/fj.201600223R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  66 in total

1.  Pendrin, encoded by the Pendred syndrome gene, resides in the apical region of renal intercalated cells and mediates bicarbonate secretion.

Authors:  I E Royaux; S M Wall; L P Karniski; L A Everett; K Suzuki; M A Knepper; E D Green
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Pendrin localizes to the adrenal medulla and modulates catecholamine release.

Authors:  Yoskaly Lazo-Fernandez; Greti Aguilera; Truyen D Pham; Annie Y Park; William H Beierwaltes; Roy L Sutliff; Jill W Verlander; Karel Pacak; Adeboye O Osunkoya; Carla L Ellis; Young Hee Kim; Gregory L Shipley; Brandi M Wynne; Robert S Hoover; Shurjo K Sen; Paul M Plotsky; Susan M Wall
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-07-14       Impact factor: 4.310

3.  Targeted disruption of mouse Pds provides insight about the inner-ear defects encountered in Pendred syndrome.

Authors:  L A Everett; I A Belyantseva; K Noben-Trauth; R Cantos; A Chen; S I Thakkar; S L Hoogstraten-Miller; B Kachar; D K Wu; E D Green
Journal:  Hum Mol Genet       Date:  2001-01-15       Impact factor: 6.150

Review 4.  Pendrin function in airway epithelia.

Authors:  Charity Nofziger; Silvia Dossena; Shoichi Suzuki; Kenji Izuhara; Markus Paulmichl
Journal:  Cell Physiol Biochem       Date:  2011-11-18

Review 5.  Biomarkers of lung damage associated with tobacco smoke in induced sputum.

Authors:  Alessia Comandini; Paola Rogliani; Alfredo Nunziata; Mario Cazzola; Giacomo Curradi; Cesare Saltini
Journal:  Respir Med       Date:  2009-07-15       Impact factor: 3.415

Review 6.  Pendred syndrome and iodide transport in the thyroid.

Authors:  Peter Kopp; Liuska Pesce; Juan Carlos Solis-S
Journal:  Trends Endocrinol Metab       Date:  2008-08-07       Impact factor: 12.015

Review 7.  How the airway smooth muscle in cystic fibrosis reacts in proinflammatory conditions: implications for airway hyper-responsiveness and asthma in cystic fibrosis.

Authors:  Sarah McCuaig; James G Martin
Journal:  Lancet Respir Med       Date:  2013-01-30       Impact factor: 30.700

Review 8.  New pulmonary therapies directed at targets other than CFTR.

Authors:  Scott H Donaldson; Luis Galietta
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

Review 9.  Targeting the IL-33/IL-13 Axis for Respiratory Viral Infections.

Authors:  Chantal Donovan; Jane E Bourke; Ross Vlahos
Journal:  Trends Pharmacol Sci       Date:  2016-01-29       Impact factor: 14.819

10.  CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.

Authors:  Liqun Zhang; Brian Button; Sherif E Gabriel; Susan Burkett; Yu Yan; Mario H Skiadopoulos; Yan Li Dang; Leatrice N Vogel; Tristan McKay; April Mengos; Richard C Boucher; Peter L Collins; Raymond J Pickles
Journal:  PLoS Biol       Date:  2009-07-21       Impact factor: 8.029

View more
  23 in total

1.  Pendrin-A New Target for Diuretic Therapy?

Authors:  Carsten A Wagner
Journal:  J Am Soc Nephrol       Date:  2016-08-11       Impact factor: 10.121

2.  Nanomolar-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prosecretory Therapy of Dry Eye Diseases.

Authors:  Sujin Lee; Puay-Wah Phuan; Christian M Felix; Joseph-Anthony Tan; Marc H Levin; Alan S Verkman
Journal:  J Med Chem       Date:  2017-01-31       Impact factor: 7.446

Review 3.  The Renal Physiology of Pendrin-Positive Intercalated Cells.

Authors:  Susan M Wall; Jill W Verlander; Cesar A Romero
Journal:  Physiol Rev       Date:  2020-07-01       Impact factor: 37.312

4.  Synthesis and evaluation of tetrahydropyrazolopyridine inhibitors of anion exchange protein SLC26A4 (pendrin).

Authors:  Jie S Zhu; Julia Y Lu; Joseph-Anthony Tan; Amber A Rivera; Puay-Wah Phuan; Marina E Shatskikh; Jung-Ho Son; Peter M Haggie; Alan S Verkman; Mark J Kurth
Journal:  Bioorg Med Chem Lett       Date:  2019-07-03       Impact factor: 2.823

5.  Small-Molecule Inhibitors of Pendrin Potentiate the Diuretic Action of Furosemide.

Authors:  Onur Cil; Peter M Haggie; Puay-Wah Phuan; Joseph-Anthony Tan; Alan S Verkman
Journal:  J Am Soc Nephrol       Date:  2016-05-06       Impact factor: 10.121

6.  Interleukin-13 increases pendrin abundance to the cell surface in bronchial NCI-H292 cells via Rho/actin signaling.

Authors:  Annamaria Russo; Marianna Ranieri; Annarita Di Mise; Silvia Dossena; Tommaso Pellegrino; Emilia Furia; Charity Nofziger; Lucantonio Debellis; Markus Paulmichl; Giovanna Valenti; Grazia Tamma
Journal:  Pflugers Arch       Date:  2017-04-04       Impact factor: 3.657

Review 7.  Emerging Targets of Diuretic Therapy.

Authors:  C-J Cheng; A R Rodan; C-L Huang
Journal:  Clin Pharmacol Ther       Date:  2017-07-10       Impact factor: 6.875

8.  4,8-Dimethylcoumarin Inhibitors of Intestinal Anion Exchanger slc26a3 (Downregulated in Adenoma) for Anti-Absorptive Therapy of Constipation.

Authors:  Sujin Lee; Onur Cil; Peter M Haggie; Alan S Verkman
Journal:  J Med Chem       Date:  2019-09-03       Impact factor: 7.446

9.  SLC26A3 inhibitor identified in small molecule screen blocks colonic fluid absorption and reduces constipation.

Authors:  Peter M Haggie; Onur Cil; Sujin Lee; Joseph-Anthony Tan; Amber A Rivera; Puay-Wah Phuan; Alan S Verkman
Journal:  JCI Insight       Date:  2018-07-26

10.  Increased expression of ATP12A proton pump in cystic fibrosis airways.

Authors:  Paolo Scudieri; Ilaria Musante; Emanuela Caci; Arianna Venturini; Patrizia Morelli; Christine Walter; Davide Tosi; Alessandro Palleschi; Pablo Martin-Vasallo; Isabelle Sermet-Gaudelus; Gabrielle Planelles; Gilles Crambert; Luis Jv Galietta
Journal:  JCI Insight       Date:  2018-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.